Bone Biologics is pursuing a better and more effective way of dealing with back pain requiring surgery by developing bone regeneration in spinal fusion using the recombinant human protein known as NELL-1/DBX. The company released its 1Q2024 financial results, which continue to show a commitment to getting the company's primary treatment through the approval process and to patients as soon as possible as testing begins.
